Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

Starting soon · Phase 2

Conditions studied: Renal Cell Carcinoma (RCC)

In brief

Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy

Key facts

Study ID

NCT07627464

Run by

Tianjin Medical University Cancer Institute and Hospital

People needed

144

Starts

2026-05-31

Expected to finish

2029-12-31

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged between 18 and 75 years, inclusive.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy.
• Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.

You may not qualify if…

• Subjects with a solitary kidney tumor.
• Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).
• Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau [VHL] disease).
• Subjects with a prior history of renal transplantation.

Where it is running

• Peking University Third Hospital — Beijing, China
• Jilin Provincial Cancer Hospital — Changchun, China
• Hunan Provincial Cancer Hospital — Changsha, China
• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China
• Yunnan Provincial Cancer Hospital — Kunming, China
• Nanjing Drum Tower Hospital — Nanjing, China
• The First Affiliated Hospital of Guangxi Medical University — Nanning, China
• The Affiliated Hospital of Qingdao University — Qingdao, China
• Huadong Hospital Affiliated to Fudan University — Shanghai, China
• Liaoning Provincial Cancer Hospital — Shenyang, China
• Shanxi Province Cancer Hospital — Taiyuan, China
• Tianjin Medical University Cancer Institute and Hospital — Tianjin, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.